Aminoguanidine Hcl

Aminoguanidine Hcl and pregnancy

Not Recommended

• Absorbed into the body
• Fetal development

Aminoguanidine HCl is a synthetic compound used in cosmetics as an anti-glycation agent to prevent protein crosslinking that contributes to skin aging. It works by inhibiting the formation of advanced glycation end products (AGEs). While it has anti-aging properties, its use during pregnancy raises significant concerns. The primary concern with aminoguanidine during pregnancy relates to its pharmaceutical history and mechanism of action. When tested as an oral medication for diabetes complications, clinical trials were discontinued due to adverse effects including vitamin B6 deficiency, anemia, liver enzyme abnormalities, and flu-like symptoms. While these were from oral use at higher doses than cosmetic application, the compound's ability to interfere with biochemical processes raises concerns. There are no studies specifically evaluating the safety of topical aminoguanidine during pregnancy, and its systemic absorption through skin is not well characterized. Given its mechanism of action in blocking glycation processes, which are normal biochemical reactions, there is theoretical concern about interference with fetal development. Most dermatologists and obstetricians recommend avoiding aminoguanidine during pregnancy due to the lack of safety data and concerns from its pharmaceutical development. The precautionary principle suggests choosing well-studied alternatives for anti-aging benefits. No regulatory body has specifically evaluated its safety for use during pregnancy.

Aminoguanidine Hcl and breastfeeding

Not Recommended

• Passes into breast milk
• Infant exposure

Aminoguanidine HCl is an anti-glycation agent used in anti-aging cosmetics. During breastfeeding, the concern centers on potential absorption through the skin and transfer to breast milk, though specific data on this pathway is absent. The compound's pharmaceutical history reveals that when taken orally, aminoguanidine caused adverse effects including vitamin B6 deficiency and anemia, which led to discontinued clinical trials. While topical application involves much lower systemic exposure than oral administration, the lack of data on dermal absorption and milk transfer is concerning. Given that the compound can interfere with normal biochemical processes, and that its effects on breastfed infants are completely unknown, most healthcare providers would advise caution. Due to the absence of safety data specific to breastfeeding and concerns from pharmaceutical studies, most dermatologists recommend avoiding aminoguanidine while breastfeeding. The AAD generally suggests that mothers avoid cosmetic ingredients with unknown safety profiles when well-studied alternatives are available for the same benefits.

Aminoguanidine Hcl and postpartum

Caution Advised

• Irritant

Aminoguanidine HCl is an anti-glycation agent that helps prevent the formation of advanced glycation end products (AGEs), which contribute to skin aging. For postpartum women not breastfeeding, concerns are primarily related to general safety rather than specific postpartum issues. The ingredient's pharmaceutical development history raises some caution flags, as oral clinical trials were discontinued due to adverse effects. However, topical cosmetic use involves much lower systemic exposure. Postpartum women may experience increased skin sensitivity due to hormonal fluctuations, which could make irritation from this compound more noticeable. Without robust safety data for topical use, a cautious approach is reasonable, though the risks are lower than during pregnancy or breastfeeding.

Aminoguanidine Hcl and trying to conceive

Not Recommended

• Absorbed into the body

Aminoguanidine HCl is an anti-glycation agent used in anti-aging cosmetics. For women trying to conceive, the same concerns that apply during pregnancy are relevant, since conception timing is often uncertain and early pregnancy exposure should be avoided. Given the lack of reproductive safety data and concerns from pharmaceutical development (clinical trials showed adverse effects including vitamin B6 deficiency and anemia), most healthcare providers recommend that women trying to conceive follow pregnancy-safe guidelines. The precautionary approach is warranted given the unknown effects on early embryonic development and the availability of safer alternatives for anti-aging benefits.

Aminoguanidine Hcl and PCOS

Safe to Use

Aminoguanidine HCl functions as an anti-glycation agent in cosmetics, preventing the formation of advanced glycation end products (AGEs) that accelerate skin aging. For women with PCOS, this ingredient has no known effects on hormonal balance, androgen levels, or insulin sensitivity. Interestingly, aminoguanidine has been studied in the context of diabetes and metabolic syndrome, conditions that share some pathophysiology with PCOS. In research settings, aminoguanidine has shown anti-inflammatory properties and may help reduce oxidative stress. However, these studies involved systemic administration, not topical application. There is no evidence that topical cosmetic use affects PCOS symptoms or hormonal status. Women with PCOS can use cosmetic products containing aminoguanidine without concern for hormonal interactions. The ingredient does not affect androgen levels, menstrual regularity, or insulin resistance. Any potential benefits for inflammation would be localized to the skin rather than systemic.

Aminoguanidine Hcl and general use

Caution Advised

• Irritant

Aminoguanidine HCl is a synthetic compound used in cosmetics as an anti-glycation agent, meaning it helps prevent the formation of advanced glycation end products (AGEs) that contribute to skin aging, wrinkles, and loss of elasticity. It works by blocking the crosslinking of proteins with sugars, a process that accelerates visible signs of aging. While aminoguanidine has promising anti-aging properties, its safety profile in cosmetics is not well-established. The compound was extensively studied as a pharmaceutical treatment for diabetes complications but failed in clinical trials due to adverse effects including vitamin B6 deficiency, flu-like symptoms, liver enzyme abnormalities, and anemia. These effects occurred with oral administration at doses higher than would be absorbed from cosmetic use, but they raise questions about the compound's safety. Topical cosmetic use involves much lower systemic exposure, but specific safety studies for dermal application are limited. The ingredient may cause skin irritation in some individuals. Aminoguanidine is not specifically prohibited in cosmetics by the FDA or EU Cosmetics Regulation, but its use remains uncommon in mainstream products, likely due to limited safety data and its problematic pharmaceutical history. For most people, the risks from occasional topical use are likely minimal, but individuals with sensitive skin or those seeking well-studied anti-aging ingredients may prefer alternatives like niacinamide, retinoids, or vitamin C.

Everything else flagged for the same profiles

• Flagged in pregnancy
• Flagged in breastfeeding
• Flagged in trying to conceive
• Flagged in postpartum

Related ingredients

Ingredients suggested in place of Aminoguanidine Hcl, each one with its own page here.

• Niacinamide
• Hyaluronic Acid

Ingredients that raise the same concerns.

• Cocamide MEAFetal development, Infant exposure, Passes into breast milk
• CamphorFetal development, Infant exposure, Passes into breast milk
• Juniperus Mexicana OilFetal development, Infant exposure, Passes into breast milk
• Cinnamomum Camphora Bark OilFetal development, Infant exposure, Passes into breast milk
• ResorcinolFetal development, Infant exposure, Passes into breast milk
• SilverFetal development, Infant exposure, Passes into breast milk

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on 15 September 2026.